M&A Deal Summary |
|
|---|---|
| Date | 2019-04-16 |
| Target | Lin Education |
| Sector | Technology Hardware |
| Buyer(s) | Foxway |
| Sellers(s) | Summa Equity |
| Deal Type | Add-on Acquisition |
SEARCH BY
Foxway is a supplier of IT lifecycle management solutions for large corporations. Foxway enables large companies and institutions to manage their physical IT assets to maximizes their use and improve quality and efficiency. Foxway was founded in 2009 and is based in Vaxjo, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Technology Hardware M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: Sweden M&A | 1 of 1 |
| Year: 2019 M&A | 1 of 1 |
| Category | Private Equity Firm |
|---|---|
| Founded | 2016 |
| PE ASSETS | 14.0B SEK |
| Size | Middle-Market |
| Type | Sector Agnostic |
Summa Equity is a private equity firm that looks to invest €10 to €50 million per transaction and pursues growing companies with significant business relations in the Nordic region. Summa Equity was formed in 2016 and is headquartered in Stockholm, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 8 |
| Sector: Technology Hardware M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 3 |
| Country: Sweden M&A | 1 of 5 |
| Year: 2019 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-03-12 |
Olink
Uppsala, Sweden Olink provides leading solutions for advanced proteomics research and development, enabling biopharmaceutical companies and leading academic researchers to quickly and efficiently understand diseases at the protein level. Olink's proprietary technology, Proximity Extension Assay (PEA), enables high-throughput protein analysis for the very large installed base of qPCR and next-generation sequencing readout systems on the market. Olink was founded in 2016 and is based in Uppsala, Sweden. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-10-14 |
Sengenics
Singapore, Singapore Sengenics is an operator of functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune, neurodegenerative, or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Sengenics was founded in 2008 and is based in Singapore. |
Buy | - |
